RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Stock

GlaxoSmithKline Stocks 2024

GlaxoSmithKline Stocks

4.11 B

Ticker

GSK.L

ISIN

GB0009252882

WKN

940561

In 2024, GlaxoSmithKline had 4.11 B outstanding stocks, a 0% change from the 4.11 B stocks in the previous year.

The GlaxoSmithKline Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2029e4.11
2028e4.11
2027e4.11
2026e4.11
2025e4.11
2024e4.11
20234.11
20224.08
20214.05
20204.03
20194.01
20183.98
20173.95
20163.93
20154.89
20144.87
20134.92
20124.99
20115.1
20105.13
20095.11
20085.23
20075.57
20065.7
20055.72
20045.75

GlaxoSmithKline shares outstanding

The number of shares was GlaxoSmithKline in 2023 — This indicates how many shares 4.111 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlaxoSmithKline earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlaxoSmithKline's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlaxoSmithKline’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlaxoSmithKline's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GlaxoSmithKline Aktienanalyse

What does GlaxoSmithKline do?

GlaxoSmithKline PLC is a globally leading pharmaceutical company headquartered in London, UK. The company's history dates back to 1873 when the Burroughs Wellcome & Co firm was founded. In 2000, the company merged with Glaxo Wellcome to form the current GlaxoSmithKline PLC. GlaxoSmithKline's business model is to provide medical solutions for various diseases and health problems. The company heavily invests in research and development to develop new drugs and vaccines. It collaborates closely with government agencies, hospitals, doctors, and patient organizations to ensure better access to its products. The company is divided into three different divisions: Pharma, Vaccines, and Consumer Healthcare. The Pharma division is the largest and includes areas such as oncology, immunology, neuroscience, respiratory, and infectious diseases. GlaxoSmithKline is a leader in HIV treatment and is also active in the development of cancer drugs. The Vaccines division of GlaxoSmithKline is also very large and includes vaccines against various infectious diseases such as pneumococcus, influenza, and meningitis. It is also working on the development of vaccines against COVID-19. GlaxoSmithKline's Consumer Healthcare division includes products such as Sensodyne, Voltaren, Nicotinell, and Aquafresh. These products operate in the areas of oral health, pain relief, and smoking cessation. The focus is on a wide range of over-the-counter products available in pharmacies and supermarkets. An example of an important product of GlaxoSmithKline is the malaria vaccine developed in collaboration with the University of Oxford. The vaccine has the potential to save millions of lives in Africa. Currently, the vaccine is being tested in several African countries. GlaxoSmithKline PLC has also faced some controversies in the past, particularly related to the marketing of antidepressants. However, the company has taken measures to increase the transparency of its practices and operate ethically. Overall, GlaxoSmithKline is a significant pharmaceutical company that offers a wide range of medical products and solutions. It heavily invests in research and development to develop new products that can improve people's lives. The company also adopts an ethical approach in its business and advocates for better access to its products. GlaxoSmithKline ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating GlaxoSmithKline's Shares Outstanding

GlaxoSmithKline's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in GlaxoSmithKline’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding GlaxoSmithKline’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in GlaxoSmithKline’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about GlaxoSmithKline stock

How many stocks are there of GlaxoSmithKline?

The current number of stocks of GlaxoSmithKline is 4.11 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of GlaxoSmithKline are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of GlaxoSmithKline evolved in recent years?

The number of shares of GlaxoSmithKline has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. GlaxoSmithKline as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of GlaxoSmithKline?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does GlaxoSmithKline pay?

Over the past 12 months, GlaxoSmithKline paid a dividend of 0.56 GBP . This corresponds to a dividend yield of about 3.84 %. For the coming 12 months, GlaxoSmithKline is expected to pay a dividend of 1.04 GBP.

What is the dividend yield of GlaxoSmithKline?

The current dividend yield of GlaxoSmithKline is 3.84 %.

When does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of GlaxoSmithKline?

GlaxoSmithKline paid dividends every year for the past 26 years.

What is the dividend of GlaxoSmithKline?

For the upcoming 12 months, dividends amounting to 1.04 GBP are expected. This corresponds to a dividend yield of 7.17 %.

In which sector is GlaxoSmithKline located?

GlaxoSmithKline is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline from 10/10/2024 amounting to 0.15 GBP, you needed to have the stock in your portfolio before the ex-date on 8/15/2024.

When did GlaxoSmithKline pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of GlaxoSmithKline in the year 2023?

In the year 2023, GlaxoSmithKline distributed 0.67 GBP as dividends.

In which currency does GlaxoSmithKline pay out the dividend?

The dividends of GlaxoSmithKline are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GlaxoSmithKline stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von GlaxoSmithKline

Our stock analysis for GlaxoSmithKline Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.